# Case-001 Mitapivat Minimum-Packet Readiness Gate

Date checked: 2026-05-19
Evidence label: minimum-packet readiness gate, not medical advice

## Direct Answer

After the clinician-answer ladder, the next blocker is packet readiness. The
mitapivat question should not be asked until the seven minimum domains are
label-ready and release-checked.

Case-001 should use this label:

`mitapivat_minimum_packet_readiness_ready`

## Source Refresh

The May 19 source check does not create a new therapy claim:

- TIF 2025 keeps TDT interpretation tied to diagnosis, transfusion, iron,
  organ, monitoring, HCT, gene manipulation, and disease-modifying therapy
  context.
- FDA AQVESME evidence remains adult-label, liver-safety, REMS, and interaction
  context.
- `NCT07506863` remains pediatric TDT watchlist evidence without posted results
  in the current check.

## Required Domains Before Asking

- `diagnosis_genotype_context`
- `age_weight_context`
- `transfusion_burden_context`
- `iron_organ_context`
- `liver_safety_context`
- `medication_interaction_context`
- `local_access_context`

## Readiness States

| State | Public action |
| --- | --- |
| `packet_not_ready` | Record missing-domain labels only. |
| `packet_ready_for_clinician_question` | Ask the May 17 review-readiness question through the clinician. |
| `packet_private_release_blocked` | Record `release_blocked` only. |

## Operational Rule

Use this gate before the May 17 clinician question. If any required domain is
missing, keep the lane at `packet_not_ready`. If any domain contains raw
identifiers, exact private dates, screenshots, raw messages, or patient-specific
instructions, keep it private and record only `release_blocked`.

## Biomedical Boundary

This gate does not diagnose subtype, recommend mitapivat, change care, decide
trial screening, decide access, or answer safety questions. It only decides
whether the packet is complete enough to ask a hematologist one review-readiness
question.

## Islamic Motivation Boundary

Quran 49:6 supports verification before acting on reports. Quran 55:7-9
supports measured claims and anti-exaggeration. Quran 16:43 supports qualified
expert consultation. These are research-method anchors, not biomedical
evidence.

## Sources

- [Mitapivat minimum-packet readiness gate map](../../../data/regulatory/mitapivat/2026-05-19-mitapivat-minimum-packet-readiness-gate.json)
- [Case-001 mitapivat clinician-answer action ladder](2026-05-18-case001-mitapivat-clinician-answer-action-ladder.md)
- [Case-001 mitapivat clinician-review readiness gate](2026-05-17-case001-mitapivat-clinician-review-readiness-gate.md)
- [TIF 2025 TDT guideline](https://www.ncbi.nlm.nih.gov/books/NBK614251/)
- [TIF 2025 blood transfusion chapter](https://www.ncbi.nlm.nih.gov/books/NBK614240/)
- [TIF 2025 iron overload chapter](https://www.ncbi.nlm.nih.gov/books/NBK614244/)
- [Aqvesme FDA label](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/216196s003lbl.pdf)
- [ClinicalTrials.gov NCT07506863](https://clinicaltrials.gov/study/NCT07506863)
- [Quran 49:6 verification anchor](../../islamic/quran/049-al-hujurat/006.md)
- [Quran 55:7-9 mizan anchor](../../islamic/quran/055-ar-rahman/007-009.md)
- [Quran 16:43 expert-consultation anchor](../../islamic/quran/016-an-nahl/043.md)
